Phaseline

Companies › Rohto Pharmaceutical

Rohto Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADR-002K
Mesenchymal stem cell therapy
–Phase 2Ischemic Heart DiseaseSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07192211ADR-002KPhase 2Ischemic Heart DiseaseCardiovascularSep 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nectero Medical Beijing Inno Medicine Cell Biopeutics Resources Sdn Bhd TR Therapeutics Kerecis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.